Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone plus prednisone with or without abemaciclib in metastatic castration-resistant prostate cancer
2023-506777-36-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Abemaciclib arm with Placebo arm (2 arms). Primary endpoint: Radiographic progression-free survival. Planned start Feb 2024; status: authorised.
02
Drugs
abemaciclib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2023-506777-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506777-36-00.